Vol. I · No. 33
Thursday, August 13, 2026
Issue: Summer · 2026
Established · MMXXVI
Geroevidence
— The evidence base for longevity medicine —
Indexed by PubMed · CTG · Cochrane
Editorial team · geroevidence.com
Subscription · app.geroevidence.com
Geroevidence·Editorial desk·clinical trials

DECLARE-TIMI 58: dapagliflozin, cardiovascular outcomes, and the longevity implications

DECLARE-TIMI 58 tested dapagliflozin in a broader, lower-risk population than EMPA-REG. What it found and what the implications are for longevity use.

By Geroevidence editorial team·Published 19 July 2026·Category clinical trials·11 min read
§ Overview

DECLARE-TIMI 58 tested dapagliflozin in a broader, lower-risk population than EMPA-REG. What it found and what the implications are for longevity use.

Evidence tier: Strong. Drug class: SGLT2 inhibitor. This profile synthesizes the published human trial evidence. The full profile with all indexed papers, active trial alerts, and tier history is available to subscribers.

§ Key human evidence
RCT
DECLARE-TIMI 58 — New England Journal of Medicine, 2018
n=17,160
Type 2 diabetes patients — broadest population of any SGLT2i trial. ~60% had multiple CV risk factors but no established CVD. Dapagliflozin 10mg versus placebo. Co-primary endpoints: MACE (non-inferior, HR 0.93, p=0.17 for superiority) and CV death/HF hospitalization (superior, HR 0.83, p=0.005). Unlike EMPA-REG, MACE reduction was not statistically significant in the overall population — but HF hospitalization was significantly reduced.
Primary prevention subgroup
DECLARE-TIMI 58 primary prevention analysis
n=~10,000
Subgroup analysis of participants without established CVD. In this lower-risk population, dapagliflozin showed numerically similar HF hospitalization reduction. MACE HR 0.93 in primary prevention subgroup — directionally consistent but not powered for significance. Relevant for longevity medicine practitioners considering SGLT2i in patients without established CVD.
Renal outcomes
DECLARE-TIMI 58 renal analysis — Lancet Diabetes Endocrinology, 2019
n=17,160
Significant reduction in composite renal endpoint (HR 0.76, 95% CI 0.67–0.87). eGFR decline attenuated versus placebo. Renal protection effect now considered a class effect of SGLT2 inhibitors. Relevant for longevity medicine given the high prevalence of CKD in aging populations and the association of renal function decline with mortality.
§ The honest clinical position

Every Geroevidence profile ends with an honest assessment of what the evidence supports and what it does not. This intervention is rated Strong based on the published human trial evidence indexed above.

The full honest clinical assessment — including evidence tier rationale, key limitations, and what trials would be needed to upgrade the tier — is in the subscriber profile. The summary: the mechanistic basis is coherent and human trial data is available; the specific clinical applications and limitations are detailed in the full profile.

This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.

Full evidence profile
All indexed papers · active trials · daily alerts
Start free trial →
14 DAYS FREE · NO CARD REQUIRED
Top interventions by evidence
GLP-1 agonists
CV outcome trials · SELECT
Strong
SGLT2 inhibitors
EMPA-REG · DECLARE
Strong
Rapamycin
mTOR inhibitor · PEARL
Moderate View all interventions →